BioSpace News Archive

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its unaudited financial results for the first quarter ended March 31, 2022.

Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on the ongoing first-in-human clinical trial of GRN-300 at the upcoming ASCO 2022 Annual Meeting.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 70 individuals hired by Sarepta in May 2022.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended March 31, 2022.

Twist Bioscience Corporation today announced the launch of the Twist Human Methylome Panel, a product now available to customers that can advance applications in cancer metastasis, human development and functional genetics.

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advance solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago, IL, on June 3-7, 2022.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the Phase 3 pivotal trial of UPLIZNA in NMOSD illustrating the treatment’s effectiveness among patients with different genetic make-ups.

CEC Oncology announces four abstracts accepted for publication in the Professional Development and Education Advances track of the 2022 ASCO Annual Meeting (https://conferences.asco.org/am/attend #ASCO22).